The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Iovance Biotherapeutics Inc (Iovance) is a biopharmaceutical company. It focuses on the development and commercialization of novel immunotherapy products for treating various cancers. The company develops products based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance's major products include Amtagvi (lifileucel), an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer, and Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen. The company's products are primarily used for treating adult patients with unresectable or metastatic melanoma. It operates a manufacturing facility in Philadelphia and a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.Iovance Biotherapeutics Inc Key Recent Developments
- Sep 17, 2025: Advancing Cancer Research Brings New Hope for Patients Worldwide
- Aug 29, 2025: Iovance Biotherapeutics to Present at Upcoming Conferences
- Jul 15, 2025: Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
- Jul 10, 2025: Iovance Biotherapeutics Names Marc Theoret as Senior Vice President, Regulatory Strategy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Werewolf Therapeutics Inc
- TILT Biotherapeutics Ltd
- Sumitomo Chemical Co Ltd
- Seagen Inc
- Sanofi
- Roche Diagnostics International Ltd
- Replimune Group Inc
- OncoSec Medical Inc
- Obsidian Therapeutics Inc
- Nektar Therapeutics
- Moderna Inc
- Merck & Co Inc
- Marker Therapeutics Inc
- Lyell Immunopharma Inc
- KSQ Therapeutics Inc
- IO Biotech Inc
- Intima Bioscience Inc
- Instil Bio Inc
- Immunocore Holdings Plc
- Immatics NV
- Iltoo Pharma
- Genmab AS
- Exelixis Inc
- Eisai Co Ltd
- Daiichi Sankyo Co Ltd
- Copenhagen University Hospital at Herlev
- Checkmate Pharmaceuticals Inc
- Bristol-Myers Squibb Co
- Biosyngen Pte Ltd
- BioNTech SE
- BeyondSpring Inc
- AstraZeneca Plc
- Amgen Inc
- Alkermes Plc
- Alaunos Therapeutics Inc
- Agenus Inc
- Adaptimmune Therapeutics Plc
- Achilles Therapeutics Plc
- Aceragen Inc